Renal denervation in patients with symptomatic chronic heart failure despite resynchronization therapy : a pilot study by Drożdż, Tomasz et al.
240 Advances in Interventional Cardiology 2019; 15, 2 (56)
Original paper
Corresponding author: 
Tomasz Drożdż MD, First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical  
College, 17 Kopernika St, 31-501 Krakow, Poland, phone: +48 12 424 73 00, fax: +48 12 424 73 20, e-mail: tomek_drozdz@wp.pl 
Received: 7.09.2018, accepted: 14.02.2019.
Renal denervation in patients with symptomatic  
chronic heart failure despite resynchronization therapy – 
a pilot study
Tomasz Drożdż, Marek Jastrzębski, Paweł Moskal, Aleksander Kusiak, Agnieszka Bednarek,  
Katarzyna Styczkiewicz, Piotr Jankowski, Danuta Czarnecka
First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland 
Adv Interv Cardiol 2019; 15, 2 (56): 240–246
DOI: https://doi.org/10.5114/aic.2019.86017
A b s t r a c t
Introduction: Renal denervation (RD) has been shown to decrease sympathetic function in patients with hypertension. Its ef-
ficacy in symptomatic chronic heart failure (CHF) patients not responding to cardiac resynchronization therapy (CRT) has not been 
evaluated. 
Aim: To assess whether a less invasive treatment method – renal denervation – is safe in symptomatic heart failure patients 
despite optimal medical treatment and resynchronization therapy and whether it is associated with an improvement in clinical 
status, exercise capacity and hemodynamic parameters. 
Material and methods: The study was an open-label, randomized, controlled clinical trial. Patients were divided into an inter-
vention (RD) and a control group. Clinical data collection, blood pressure (BP) measurements, echocardiography, 6-minute walk test 
(6MWT) and laboratory tests were performed before, 6 and 12 months after RD. The patients were followed-up to 24 months.
Results: We included 20 patients aged 52.0 to 86.0 years (median age: 71.5 years), 15 males and 5 females with median left 
ventricular ejection fraction (LVEF) of 32.5%, body mass index 31.3 kg/m2. Renal denervation was safe, no significant adverse effects 
were registered. There were no significant differences in LVEF, BP, 6MWT and N-terminal prohormone of brain natriuretic peptide 
(NT-proBNP) concentration 6 and 12 months after RD or control.
Conclusions: Our results indicate that RD in CHF patients not responding to CRT is safe and does not worsen exercise capacity 
and hemodynamic parameters. 
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S u m m a r y
Renal denervation (RD) in symptomatic chronic heart failure patients not responding to cardiac resynchronization therapy 
has not been evaluated. In our patients RD was safe, no serious adverse effects were registered. We detected no significant re-
lation between renal artery denervation and clinical status, exercise capacity and hemodynamic parameters in optimally treated 
heart failure patients with systolic blood pressure over 110 mm Hg. Renal denervation was a safe procedure in this population. 
Introduction
Currently, due to advances in treatment, we observe 
an increase in life expectancy in patients with hyper-
tension and coronary artery disease. These diseases are 
among the leading causes of heart failure development 
and, as a result of better survival rate and longer lifes-
pan in these patients, chronic heart failure (CHF) is in-
creasing in prevalence [1–3]. Despite the unquestionable 
progress in treatment of these predisposing diseases 
the mortality rate of CHF patients has only slightly im-
proved in recent years [4]. Cardiac resynchronization 
therapy (CRT) – a  method of heart stimulation – was 
introduced into the treatment of heart failure almost 
20 years ago [5]. The CRT is used in symptomatic patients 
with advanced stages of heart failure, despite optimal 
pharmacological therapy, with accompanying intraven-
tricular conduction block. It is one of the most promis-
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ing therapies, with a confirmed beneficial effect on heart 
failure outcomes [6]. However, there still remains a group 
of patients in which CRT it is not effective. About one 
third of patients who receive CRT do not have a mean-
ingful clinical improvement. The reasons for this are 
complex and still not fully understood [7]. To date in this 
group of patients only left ventricular assist devices and 
heart transplant remain possible therapeutic modalities, 
but the accessibility of these methods is still insufficient. 
Aim
We aimed to assess whether a  less invasive treat-
ment method – renal denervation – is safe in symp-
tomatic heart failure patients despite optimal medical 
treatment and resynchronization therapy and whether 
it is associated with an improvement in clinical status, 
exercise capacity and hemodynamic parameters. 
Material and methods
Study design
The study was conducted as an open-label, prospec-
tive, randomized, controlled clinical trial where patients 
were assigned to an intervention group undergoing the 
renal denervation procedure and a control group with no 
intervention based on the results of coin toss. Peripheral 
blood pressure (BP) measurements, transthoracic echo-
cardiography, 6-minute walk test (6MWT), renal function 
assessment and biochemistry were performed at base-
line and after 6 and 12 months. The patients were fol-
lowed-up to 24 months. Optimal pharmacotherapy ac-
cording to current European Society of Cardiology (ESC) 
guidelines was kept constant throughout the study [1, 2]. 
The echocardiographic optimization of atrioventricular 
and interventricular delay in CRT was performed for each 
patient before the study. 
Ethics
The study was performed in accordance with the 
1975 Declaration of Helsinki for Human Research and 
approved by the Jagiellonian University Bioethical Com-
mittee. Patients were included only if they gave their in-
formed consent. The study is registered in the ClinicalTri-
als.gov repository (id: NCT02329145).
Study population 
Adult CHF patients who met the following criteria 
were enrolled in this study: NYHA class II–IV; implanted 
resynchronization pacemaker according to current Eu-
ropean guidelines at least 6 months prior to inclusion; 
persistent symptoms, defined as a lack of improvement 
in subjective dyspnea or exercise tolerance, despite sta-
ble pharmacological treatment over the previous 4 weeks 
(with ACE inhibitor and b-blocker unless contraindicat-
ed) and optimal biventricular (BIV) pacing (no less than 
98% of paced QRS complexes); left ventricular ejection 
fraction (LVEF) equal to or lower than 35% in echocar-
diographic assessment prior to CRT implantation; es-
timated glomerular filtration rate (eGFR according to 
Modification of Diet in Renal Disease (MDRD) formula 
≥ 30 ml/min/1.73 m2).
We excluded patients with renal artery anatomy not 
eligible for denervation (< 4 mm diameter, < 20 mm in 
length) [8]; history of prior renal artery intervention; sin-
gle functioning kidney; systolic BP < 110 mm Hg; acute 
coronary syndrome or cerebrovascular event within last 
3 months; serious medical conditions which may adverse-
ly affect safety such as significant peripheral vascular 
disease, abdominal aortic aneurysm, bleeding disorders 
(thrombocytopenia, hemophilia, or significant anemia) or 
pregnancy.
Renal denervation
Patients in the treatment group underwent renal ar-
tery denervation performed by an endovascular cathe-
ter-based approach in order to disrupt renal sympathetic 
nerves. A  Symplicity radiofrequency renal-denervation 
catheter (Medtronic) was used. The central artery tree 
and renal artery were accessed by the femoral artery. The 
catheter was connected to a radiofrequency (RF) genera-
tor and multiple RF applications were performed in order 
to disrupt renal sympathetic nerves. We performed up 
to six radiofrequency ablations of up to 2 min duration 
that were separated both longitudinally and rotationally 
within each renal artery. Renal evaluations using duplex 
scan were performed in order to exclude baseline reno-
vascular abnormalities and possible complications of the 
procedure, the main one being renal artery stenosis [8].
Peripheral blood pressure measurement
Office BP measurement was performed according 
to standards of the Polish Society of Hypertension [9]. 
Twenty-four-hour peripheral blood pressure monitoring 
was performed with the SpaceLabs 90207 monitor (Red-
mond, WA, USA). BP measurements were performed dai-
ly every 15 min (6 a.m. to 22 p.m.) and every 30 min at 
night (22.00 p.m. to 6.00 a.m.). Based on the acquired 
recordings mean values for systolic, diastolic blood pres-
sure was calculated for 24 h, day and night time.
Echocardiography
Echocardiography was performed using the Vivid 
7 Pro (General Electric, Fairfield, USA), with a  2.5 MHz 
probe by a single experienced operator who was blinded 
to the patients’ allocation to experimental groups. Mea-
surements were assessed according to the European So-
ciety of Echocardiography standards [10]. Left ventricle 
mass was calculated using the Devereux formula [10].
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Six-minute walk test (6MWT)
The 6-minute walk test was performed in patients af-
ter a 10-minute, seated rest period. Patients were asked 
to march at their own pace, on a flat and level surface 
in an empty corridor. Patients were informed about the 
progress of the test on a regular basis; at the end of the 
6-minute period, the total distance walked was mea-
sured. At baseline and after the test blood pressure and 
oxygen saturation were also measured [11].
Biochemistry
Biochemical parameters such as serum N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP), 
creatinine (with the calculation of eGFR) and electrolytes 
were measured.
End points of the study
Primary end points were: 1) number of hospital-
izations due to heart failure worsening within 1 year; 
2) change in NYHA class within 1 year; 3) change in 
6-minute walk test distance within 1 year. Additionally 
we evaluated the change in LVEF, BP values and NT-proB-
NP concentrations.
Safety
Safety parameters included death, stroke, myocardial 
infarction, renal artery stenosis or dissection, pseudoan-
eurysm at the femoral access site, bleeding, and reduc-
tion in eGFR.
Statistical analysis
All data were analyzed using the Statistica PL v.12.0 
software. Categorical variables are reported as percentag-
es and continuous variables as median and interquartile 
ranges when data distribution differed from the normal. 
The c2 tests were applied to all categorical variables. For 
continuous variables, the Mann-Whitney test, the t-test 
for paired samples or the Wilcoxon matched pairs test 
was used. Effects for which the p-value was lower than 
the assumed level of significance α = 0.05 (p < 0.05) were 
considered significant.
Results
Patient cohort
We screened 24 patients for being eligible for inclu-
sion. In 4 patients in abdominal computed tomography 
we found tumors with suspicion of malignancy. These 
patients were excluded from the study [12]. Twenty pa-
tients aged 52.0 to 86.0 years (median age: 71.5 years), 
15 males and 5 females with median LVEF of 32.5%, 
in NYHA class II and III, median body mass index (BMI) 
31.3 kg/m2 were randomized. Secondary forms of car-
diomyopathy were the most prevalent causes of CHF – 
12 (60%) patients had ischemic cardiomyopathy. Eight 
(40%) patients had dilated cardiomyopathy of unknown 
etiology. The median QRS complex duration prior to 
CRT implantation was 150 ms and after the procedure 
120 ms. Nineteen (95%) patients had left bundle branch 
block morphology and 1 patient had right bundle branch 
block. The median LVEF prior to CRT implantation was 
27%. The clinical characteristics of enrolled patients are 
shown in Table I separately for the intervention and con-
trol groups. There were no significant differences in base-
line characteristics according to group assignment.
The mean total time of denervation was 661 ±65 s 
for the right and 668 ±84 s for the left renal artery. The 
reduction of tissue resistance during ablation was 14.36 
±2.53 and 13.89 ±1.89%, respectively.
Primary endpoints
During 12 months of observation 3 patients in the 
RD group and 2 in the control group were rehospital-
ized due to decompesation of heart failure (p = NS) 
whereas during 24 months of observation 4 patients 
inthe RD and 5 patients incontrol group were rehospi-
talized (p = NS).
In the intervention group during 12 months of obser-
vation two patients improved from NYHA class III to II. 
In the control in 12 months 1 patient deteriorated from 
class II to III. The changes in NYHA class are presented in 
Figures 1 and 2.
The median change in 6MWT distance in the RD 
group was bigger compared to the control group, but it 
did not reach statistical significance (+38.0 (–50.0; +90.0) 
vs. 0.0 (–100.0; +40.0) m, p = 0.212).
Secondary endpoints
Table II reports the changes in main clinical variables 
6 and 12 months after renal denervation or allocation 
to the control group. We did not observe any significant 
changes in median heart rate, office blood pressure val-
ues, 6MWT distance or NT-proBNP concentrations. 
Safety results
Renal denervation was safe, the procedure was done 
without complications in all of the patients and no sig-
nificant periprocedural adverse effects (e.g. renal artery 
stenosis or dissection, pseudoaneurysm at the femoral 
access site, bleeding) were observed. After 6 and 12 
months of observation we did not observe significant 
changes in eGFR in either the intervention or the control 
group. No patient developed renal-related symptoms.
In 2-year follow-up 1 (5%) patient from the interven-
tion group (10%) died of an unknown cause. What could 
have influenced the death is the fact that he discontinued 
the vitamin K antagonist despite indications (persistent 
AF and self-contrast of blood in echocardiography). After 
the 2-year follow-up we received information about the 
second death of a patient from the intervention group. 
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There were no strokes or myocardial infarctions during 
the course of the study. 
Discussion
To the authors’ knowledge this is the first report of 
a randomized controlled trial examining the role of renal 
denervation in patients with symptomatic heart failure 
with reduced ejection fraction not responding to resyn-
chronization therapy. We found that the procedure of 
RD in patients with CHF is safe as no long-term adverse 
events resulted from the intervention. Especially, we did 
not observe any cases of renal artery stenosis or aneu-
rysm. Furthermore, we observed no significant impair-
ment of renal function according to the estimated glo-
merular filtration rate.
The activation of the sympathetic nervous system 
is one of the pathomechanisms responsible for the de-
velopment and progression of heart failure. In chronic 
heart failure increased activity of the sympathetic and 
decreased activity of the parasympathetic system are 
present [13]. Based on previous studies involving renal 
denervation in patients with resistant hypertension, 
a decrease in the excessive activity of the sympathetic 
nervous system in heart failure patients after renal de-
nervation might be expected [14]. This knowledge has 
generated an interest in renal denervation including 
catheter-based procedures as an attractive therapeutic 
approach in the therapy of resistant hypertension. Prima-
ry clinical data from two big trials – Symplicity HTN-1 and 
HTN-2 – demonstrated that catheter-based renal sympa-
Table I. Baseline characteristics of study participants
Parameter All (n = 20) Denervation (n = 10) Control (n = 10) P-value
NYHA Class 3.0 (2.0–3.0) 3.0 (3.0–3.0) 2.5 (2.0–3.0) NS
Age [years] 71.5 (67.5–78.0) 75.0 (65.0–81.0) 71.0 (70.0–76.0) NS
Sex, male, n (%) 15 (75) 8 (80) 7 (70) NS
BMI [kg/m2] 31.3 (29.2–35.6) 31.1 (29.5–32.0) 32.1 (26.2–37.7) NS
LVEF prior to CRT (%) 27.0 (22.0–33.5) 27.5 (22.0–35.0) 27.0 (25.0–32.0) NS
LVEF at RD (%) 32.5 (27.5–37.5) 33.5 (30.0–40.0) 32.0 (25.0–36.0) NS
Heart rate [/min] 70 (63.0–75.0) 64.0 (61.0–75.0) 70.0 (64.0–75.0) NS
Office SBP [mm Hg] 125 (120–137) 124 (120–130) 132 (120–153) NS
Office DBP [mm Hg] 74 (70–80) 73 (70–80) 74 (70–78) NS
24 h SBP [mm Hg] 111 (102–118) 113 (100–118) 111 (102–119) NS
24 h DBP [mm Hg] 63 (55–68) 59 (56–68) 65 (54–69) NS
6MWT distance [m] 330 (270–415) 320 (240–330) 380 (300–440) NS
NT-proBNP [pg/ml] 1116 (491–2132) 1116 (445–1878) 1148 (537–2387) NS
HbA
1c
 (%) 6.1 (5.8–6.4) 6.3 (6.0–6.5) 5.8 (5.6–6.4) NS
Infarction, n (%) 8 (40) 5 (50) 3 (30) NS
Diabetes, n (%) 9 (45) 5 (50) 4 (40) NS
Hypertension, n (%) 15 (75) 7 (70) 8 (80) NS
History of stroke, n (%) 3 (15) 1 (10) 2 (20) NS
Hypercholesterolemia, n (%) 17 (85) 8 (40) 9 (45) NS
CKD, n (%) 6 (30) 4 (40) 2 (20) NS
CABG, n (%) 1 (5) 0 (0) 1 (10) NS
PCI, n (%) 4 (20) 4 (40) 0 (0) NS
AF, n (%) 16 (80) 8 (80) 8 (80) NS
b-Blocker, n (%) 20 (100) 10 (100) 10 (100) NS
ACEI/ARB, n (%) 17 (85) 8 (80) 9 (90) NS
MRA, n (%) 17 (85) 8 (80) 9 (90) NS
Diuretic, n (%) 19 (95) 9 (90) 10 (100) NS
Digoxin, n (%) 5 (25) 1 (10) 40 (40) NS
Values presented as median (interquartile range) or percentage. BMI – body mass index, LVEF – left ventricular ejection fraction, CRT – cardiac resynchronization 
therapy, RD – renal denervation, SBP – systolic blood pressure, DBP – diastolic blood pressure, 6MWT – 6-minute walk test, NT-proBNP – N-terminal prohormone 
of brain natriuretic peptide, HbA
1c
 – glycated hemoglobin, CKD – chronic kidney disease, CABG – coronary artery bypass graft, PCI – percutaneous coronary inter-
vention, AF – atrial fibrillation, ACEI – angiotensin-converting enzyme inhibitor, ARB – angiotensin receptor blocker, MRA – mineralocorticoid receptor antagonist, 
NYHA – New York Heart Association.
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thetic denervation can be safely used to reduce blood 
pressure within 24 months’ observation [15, 16]. How-
ever, the results of the Symplicity HTN-3 trial have not 
confirmed the blood-lowering effect of renal denervation 
[17]. However, several factors had a substantial impact 
on the results of the HTN-3 trial [18]. Later studies, like 
the multicenter, international, single-blind, randomized, 
sham-controlled SPYRAL HTN-OFF MED study showed 
in 80 patients a significant reduction in both office and 
24-h ambulatory blood pressure values in the interven-
tion group with no effect in the control group. There were 
no major adverse events in either group [19]. 
Renal denervation studies in hypertension have 
shown a positive effect of RD on cardiac remodeling such 
as a reduction in left atrial volume index [20], reduction 
in mean interventricular septum thickness, LV mass in-
dex (LVMI) and LV filling pressures and an increase in 
LVEF [21 22].
There have been several studies that evaluated the 
effect of renal denervation in patients with CHF. One 
such study is the REACH study, which showed that RD 
in patients with CHF is safe. No episodes of syncope, 
hypotension or other significant hemodynamic dys-
function were recorded during the acute phase after 
RD and renal function remained stable. Furthermore, 
6 months after RD a non-significant blood pressure re-
duction and an improvement in 6-minute walk distance 
(Δ = 27.1 ±9.7 m, p = 0.03) were observed [23]. According 
to current guidelines, 6MWT is easy to administer and 
provides strong indications for measuring the response 
to medical intervention in patients with heart failure 
[11]. In ambulatory patients with systolic heart failure, 
6MWT provides prognostic utility comparable to cardio-
pulmonary exercise tests, which is the gold standard for 
the assessment of exercise capacity in this group of pa-
tients [24]. In our study we found a non-significant im-
provement in 6MWT in patients 6 months after RD (320 
(240; 330) vs. 335 (280; 360) m, p = NS). 
In a  randomized, controlled pilot study by Chen 
et al. 60 symptomatic patients with CHF and reduced 
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Figure 1. Changes in New York Heart Association 
(NYHA) class in the denervation group
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Figure 2. Changes in New York Heart Association 
(NYHA) class in the control group
Table II. Change in clinical variables at baseline and after 6 and 12 months
Parameter From baseline to 6th month From baseline to 12th month
RD
(n = 10)
Control
(n = 10)
P-value RD
(n = 10)
Control
(n = 10)
P-value
LVEF (%) 0.0 (0.0–3.0) 2.0 (0.0; 7.0) NS 0.0 (–3.0; 7.0) 2.0 (–3.0; 8.0) NS
Heart rate [/min] –1.5 (–4.0; –1) 1.0 (0.0–5.0) NS 1.0 (–3.0; 4.0) 4.5 (2.0; 6.0) NS
Office SBP [mm Hg] –1.0 (–4.0; 20.0) 0.0 (–13.0; 15) NS 17.5 (10.0–28.0) –5.0 (–16.0; 22.0) NS
Office DBP [mm Hg] 0.0 (–2.0; 14.0) 0.0 (–5.0; 3.0) NS 8.0 (2.0–18.0) 1.5 (–1.0; 5.0) NS
24 h SBP [mm Hg] 3.0 (–9.0; 15.0) –9.0 (–15.0; 5.0) NS 7.5 (6.0; 17.0) –1.5 (–8.0; 3.0) NS
24 h DBP [mm Hg] 5.0 (–1.0; 9.0) –3.0 (–9.0; 7.0) NS 4.5 (3.0; 10.0) 2.5 (–6.0; 6.0) NS
6MWT distance [m] 20.0 (0.0; 90.0) 2.0 (–20.0; 60.0) NS 38.0 (–50.0; 90.0) 0.0 (–100.0; 40.0) NS
NT-proBNP [pg/ml] 31 (–450; 906) –69 (–347; 48) NS –11(–1059; 462) 211 (–22; 735) NS
eGFR [ml/min/1.73 m2] 0.70 (–6.0; 17.1) –0.6 (–11.2; 14.8) NS –4.1 (7.9; 0.0) 0.4 (–7.4; 6.7) NS
Values presented as median (interquartile range). RD – renal denervation, LVEF – left ventricular ejection fraction, SBP – systolic blood pressure, DBP – diastolic blood 
pressure, 6MWT – 6-minute walk test, eGFR – estimated glomerular filtration rate.
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EF (< 40%) were randomized to RD plus optimal med-
ical therapy (OMT) or only OMT. Throughout the study 
no severe adverse events were observed. Blood pressure 
was stable in both groups. Patients 6 months after RD 
showed a significant improvement in LVEF (31.1 ±5.7 vs. 
41.9 ±7.9%, p < 0.001) and 6-minute walk test distance 
(285.5 ±84.3 vs. 374.9 ±91.9 m, p = 0.043) and quali-
ty of life. NT-proBNP after RD was significantly reduced 
(p < 0.001). No significant changes in estimated glomeru-
lar filtration and no renal complications were found [25]. 
Compared to our study, the patients examined by Chen 
et al. were significantly younger, with less prevalent isch-
emic etiology and no stimulation.
Gao et al. in a study on 14 patients with CHF and ejec-
tion fraction < 45%, who received bilateral RD, observed, 
6 months after the procedure, a  significant increase 
in 6MWT distance (152.9 ±38.0 vs. 334.3 ±94.4 m, p < 
0.001) and EF (36.0 ±4.1 vs. 43.8 ±7.9%, p = 0.003). On 
the other hand, systolic BP decreased from 138.6 ±22.1 
to 123.2 ±10.5 mm Hg (p = 0.026) and diastolic BP from 
81.1 ±11.3 to 72.9 ±7.5 mm Hg (p = 0.032). The authors 
did not observe adverse results or worsening of renal 
function. However, one of the limitations of this study 
was the lack of a control group [26].
The RDT-PEF study aimed at assessing the effect of 
RD with the Symplicity catheter vs standard therapy on 
several clinical parameters (Minnesota Living with Heart 
Failure Questionnaire score, peak oxygen uptake (VO
2) 
on exercise, BNP, E/e′, LA volume index or LV mass index). 
Due to recruitment difficulties, the study was terminated 
after inclusion of only 25 patients and was underpowered 
to detect whether RD influenced the defined endpoints. 
Changes in eGFR were comparable in the two groups, but 
2 patients required balloon angioplasty during the RD to 
treat renal artery wall edema [27].
In a  study by Hopper et al. on 40 HF patients RD 
was associated with small reductions in NT-proBNP and 
120-minute glucose tolerance at 12 months with no 
RD-associated adverse effect, except for 1 case of renal 
artery occlusion [28].
These previously described beneficial effects of RD on 
BP may also extend to the preservation of renal function. 
Kiuchi et al. reported beneficial effects of RD in 24 patients 
with chronic kidney disease and refractory hypertension 
on kidney function. A  significant improvement in eGFR 
(85.4 ±34.9 vs. 64.4 ±23.9 ml/min/1.73 m2, p < 0.0001) 
and a  decrease in the median urine albumin/creatinine 
ratio (15.7 (10.3–34.2) vs. 48.5 (35.8–157.2) mg/g, p = 
0.0017) at 6 months of follow-up were present [29]. There 
were also reports of a reduction in albuminuria after RD in 
patients with resistant hypertension [30]. Furthermore, 
a reduction in Doppler sonographic renal resistive index, 
which reflects systemic and renal hemodynamics, has 
been associated with progression of renal impairment 
and which could be a potential noninvasive predictor of 
lack of response to RD, has been observed [31]. In our 
study we observed a  non-significant increase in eGFR 
after RD proving its safety in CHF patients in regard to 
renal function. Unfortunately we did not evaluate micro-
albuminuria.
Throughout the study one of the patients from the in-
tervention group died of an unknown cause at home. We 
could not associate the death with the procedure of RD, 
as no acute and follow-up disturbances have been noted. 
The studied population consisted of patients with severe 
heart failure that did not respond to optimal pharmaco- 
and electrotherapy and the worsening of the underlying 
disease was the most probable cause of death.
Our study has several strengths. Firstly, it is the first 
study regarding renal denervation in patients with CHF 
not responding to CRT. To date, there have been several 
ongoing studies concerning RD in CHF, but there are no 
studies evaluating this intervention in severe stages of 
CHF that do not benefit from CRT. So far in this scientific 
area only limited data are available. Thus the above study 
has a pilot character.
There are also a few limitations. First, the small num-
ber of patients may have resulted in the study being 
underpowered to show significant change in evaluated 
parameters. One may speculate that RD could counter-
act the progression of CHF in these patients. Thus, the 
observed improvement in exercise capacity was small and 
did not reach statistical significance. Second, the use of 
a single-electrode catheter might have led to an inability 
to create a circumferential lesion effortlessly, which un-
fortunately cannot reliably be assessed during the proce-
dure. In a 2017 position paper on the autonomic nervous 
system as a therapeutic target in heart failure from the 
Translational Research Committee of the Heart Failure 
Association of the ESC the use of such catheters is dis-
couraged. However, when the protocol of this study was 
created and introduced, newer catheters and the afore-
mentioned data were not yet available [32]. Furthermore, 
despite the increase in CRT implantation in recent years, 
the population of patients with this device who are eligi-
ble for RD is still limited due to hypotension or atheroscle-
rosis of renal arteries. The lack of a sham procedure also 
limits the power of the results.
Conclusions
We detected no significant relation between renal ar-
tery denervation and clinical status, exercise capacity and 
hemodynamic parameters in optimally treated heart fail-
ure patients with systolic blood pressure over 110 mm Hg. 
Renal denervation was a safe procedure in this popula-
tion.
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